Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

904
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
904
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

752
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
752
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

2.1K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.1K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

479
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
479
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

881
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
881

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis.

Journal of hepatology·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis.

Gut·2025
Same author

Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases.

The lancet. Gastroenterology & hepatology·2025
Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025

Related Experiment Video

Updated: Mar 28, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

168

Budd-Chiari syndrome.

Pieter Martens1, Frederik Nevens2

  • 1Department of Internal Medicine.

United European Gastroenterology Journal
|December 16, 2015
PubMed
Summary
This summary is machine-generated.

Budd-Chiari syndrome (BCS) involves hepatic outflow obstruction, often linked to prothrombotic risk factors like myeloproliferative disorders. Early diagnosis and anticoagulation, followed by interventions if needed, lead to a 90% five-year survival rate.

Keywords:
Budd-Chiari syndromeTIPSetiologyliver transplantationoutcometreatment

More Related Videos

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 28, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

168
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.0K

Area of Science:

  • Hepatology
  • Vascular Medicine
  • Hematology

Background:

  • Budd-Chiari syndrome (BCS) is a rare hepatic disorder caused by obstruction of hepatic venous outflow.
  • It is frequently associated with underlying prothrombotic risk factors, most commonly myeloproliferative disorders.
  • BCS presents diversely, mimicking other acute and chronic liver diseases, necessitating a high index of suspicion in patients with risk factors.

Purpose of the Study:

  • To outline the diagnostic approach and management strategies for Budd-Chiari syndrome.
  • To emphasize the importance of identifying and managing underlying prothrombotic risk factors.
  • To discuss the efficacy of various treatment modalities and long-term outcomes.

Main Methods:

  • Diagnosis confirmed by Doppler ultrasound, with CT or MRI for further assessment.
  • Primary treatment involves anticoagulation.
  • Interventional strategies include angioplasty, transjugular intrahepatic portosystemic shunt (TIPS), and liver transplantation for refractory cases.

Main Results:

  • Anticoagulation is the cornerstone of BCS management.
  • The majority of patients require additional invasive treatments beyond anticoagulation.
  • Proposed treatment algorithms guide interventions based on treatment response, achieving a five-year survival rate of 90%.

Conclusions:

  • Budd-Chiari syndrome requires prompt diagnosis and management of underlying prothrombotic conditions.
  • A multidisciplinary approach integrating anticoagulation and interventional procedures improves patient survival.
  • Long-term surveillance is crucial to monitor for recurrence and potential complications such as myeloproliferative disorder progression or post-transplant lymphoproliferative disorders.